Management of hyperkalemia

An update for the internist

Research output: Contribution to journalReview article

35 Citations (Scopus)

Abstract

Hyperkalemia is a clinically important electrolyte abnormality that occurs most commonly in patients with chronic kidney disease. Due to its propensity to induce electrophysiological disturbances, severe hyperkalemia is considered a medical emergency. The management of acute and chronic hyperkalemia can be achieved through the implementation of various interventions, one of which is the elimination of medications that can raise serum potassium levels. Because many such medications (especially inhibitors of the renin-angiotensin aldosterone system) have shown beneficial effects in patients with cardiovascular and renal disease, their discontinuation for reasons of hyperkalemia represent an undesirable clinical compromise. The emergence of 2 new potassium-binding medications for acute and chronic therapy of hyperkalemia may soon allow the continued use of medications such as renin-angiotensin-aldosterone system inhibitors even in patients who are prone to hyperkalemia. This review article provides an overview of the physiology and the pathophysiology of potassium metabolism and hyperkalemia, the epidemiology of hyperkalemia, and its acute and chronic management. We discuss in detail emerging data about new potassium-lowering therapies, and their potential future role in clinical practice.

Original languageEnglish (US)
Pages (from-to)1281-1287
Number of pages7
JournalAmerican Journal of Medicine
Volume128
Issue number12
DOIs
StatePublished - Jan 1 2015

Fingerprint

Hyperkalemia
Potassium
Renin-Angiotensin System
Chronic Renal Insufficiency
Electrolytes
Epidemiology
Emergencies
Cardiovascular Diseases
Kidney
Therapeutics
Serum

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Management of hyperkalemia : An update for the internist. / Kovesdy, Csaba.

In: American Journal of Medicine, Vol. 128, No. 12, 01.01.2015, p. 1281-1287.

Research output: Contribution to journalReview article

@article{529bc6467ebb49a7bc29e3ddde5cac3f,
title = "Management of hyperkalemia: An update for the internist",
abstract = "Hyperkalemia is a clinically important electrolyte abnormality that occurs most commonly in patients with chronic kidney disease. Due to its propensity to induce electrophysiological disturbances, severe hyperkalemia is considered a medical emergency. The management of acute and chronic hyperkalemia can be achieved through the implementation of various interventions, one of which is the elimination of medications that can raise serum potassium levels. Because many such medications (especially inhibitors of the renin-angiotensin aldosterone system) have shown beneficial effects in patients with cardiovascular and renal disease, their discontinuation for reasons of hyperkalemia represent an undesirable clinical compromise. The emergence of 2 new potassium-binding medications for acute and chronic therapy of hyperkalemia may soon allow the continued use of medications such as renin-angiotensin-aldosterone system inhibitors even in patients who are prone to hyperkalemia. This review article provides an overview of the physiology and the pathophysiology of potassium metabolism and hyperkalemia, the epidemiology of hyperkalemia, and its acute and chronic management. We discuss in detail emerging data about new potassium-lowering therapies, and their potential future role in clinical practice.",
author = "Csaba Kovesdy",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.amjmed.2015.05.040",
language = "English (US)",
volume = "128",
pages = "1281--1287",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Management of hyperkalemia

T2 - An update for the internist

AU - Kovesdy, Csaba

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Hyperkalemia is a clinically important electrolyte abnormality that occurs most commonly in patients with chronic kidney disease. Due to its propensity to induce electrophysiological disturbances, severe hyperkalemia is considered a medical emergency. The management of acute and chronic hyperkalemia can be achieved through the implementation of various interventions, one of which is the elimination of medications that can raise serum potassium levels. Because many such medications (especially inhibitors of the renin-angiotensin aldosterone system) have shown beneficial effects in patients with cardiovascular and renal disease, their discontinuation for reasons of hyperkalemia represent an undesirable clinical compromise. The emergence of 2 new potassium-binding medications for acute and chronic therapy of hyperkalemia may soon allow the continued use of medications such as renin-angiotensin-aldosterone system inhibitors even in patients who are prone to hyperkalemia. This review article provides an overview of the physiology and the pathophysiology of potassium metabolism and hyperkalemia, the epidemiology of hyperkalemia, and its acute and chronic management. We discuss in detail emerging data about new potassium-lowering therapies, and their potential future role in clinical practice.

AB - Hyperkalemia is a clinically important electrolyte abnormality that occurs most commonly in patients with chronic kidney disease. Due to its propensity to induce electrophysiological disturbances, severe hyperkalemia is considered a medical emergency. The management of acute and chronic hyperkalemia can be achieved through the implementation of various interventions, one of which is the elimination of medications that can raise serum potassium levels. Because many such medications (especially inhibitors of the renin-angiotensin aldosterone system) have shown beneficial effects in patients with cardiovascular and renal disease, their discontinuation for reasons of hyperkalemia represent an undesirable clinical compromise. The emergence of 2 new potassium-binding medications for acute and chronic therapy of hyperkalemia may soon allow the continued use of medications such as renin-angiotensin-aldosterone system inhibitors even in patients who are prone to hyperkalemia. This review article provides an overview of the physiology and the pathophysiology of potassium metabolism and hyperkalemia, the epidemiology of hyperkalemia, and its acute and chronic management. We discuss in detail emerging data about new potassium-lowering therapies, and their potential future role in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=84947862944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947862944&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2015.05.040

DO - 10.1016/j.amjmed.2015.05.040

M3 - Review article

VL - 128

SP - 1281

EP - 1287

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 12

ER -